| Bid price | 27.00 | Open price | 27.93 |
|---|---|---|---|
| Ask price | 27.75 | Prev close | 27.38 |
| High price | 27.93 | Spread | 2.70% |
| Low price | 27.00 | Volume | 19,836 |
Register now for FREE live Proteome Sciences share prices, Proteome Sciences stock quotes, charts, trades and FREE Proteome Sciences company fundamentals, market news and much much more. Why not upgrade to a premium service and get Proteome Sciences Level 2 Data, indepth research tools and investor commentary for Proteome Sciences (PRM) and other London Stock Exchange equities.
Register now for FREE Proteome Sciences share price charts
| Name | Proteome Sciences | Epic | PRM |
|---|---|---|---|
| Activites | Researches and develops applied proteomics, using proprietary techniques to detect diseases for diagnostic applications | Reuters | PRM.L |
| ISIN | GB0003104196 | Google Finance | LON:PRM |
| Share Price (p) | 27.38 | Prev. Share Price (p) | 27.38 |
|---|---|---|---|
| Shares in Issue (m) | 192 | Market Cap (£m) | 52 |
| PE Ratio (x) | 12.54 | Div per share (p) | 0.00 |
| Div yield (%) | 0.00 | Div cover (x) | |
| EPS (p) | 2.80 | PEG |
Register now for FREE Proteome Sciences company fundamentals
| Dec.Date | Type | Director | Pos | No. of Shares |
|---|---|---|---|---|
| 06/07/2010 | PLAC | R Steve Harris | CH | 24,199 |
| 06/07/2010 | PLAC | James Malthouse | FD | 130,031 |
| 06/07/2010 | PLAC | William Dawson | NED | 5,248 |
| 31/05/2008 | EXR | Christopher Pearce | CEO | 450,000 |
| 31/05/2008 | EXR | Christopher Pearce | CEO | 433,124 |
/* */ RNS Number : 0913C Proteome Sciences PLC 30 April 2012 Proteome Sciences plc (the "Company") Total Voting Rights In accordance with the FSA's Disclosure and Transparency Rule 5.6.1, Proteome Sciences plc (the "Company") announces...
More Proteome Sciences Company News >>
Register now for FREE Proteome Sciences company news
Does anyone have an opinion on PRM. No comparable news for a while. Price seems to be sliding once again.
WELL INFORMED CITY SOURCE REVEALED IMPORTANT MEETING TOOK PLACE WITHIN LAST WEEK AND A MAJOR DEAL WILL BE ANNOUNCED WITHIN DAYS.THE SHARES WILL BE RE-RATED SUBSTANTIALLY FOLLOWING THE ANNOUNCEMENT.
After years of promise, PRM seems to be on the verge of a breakthrough into the big league. Deals have been signed in the last six months which will commercialise their stroke and bse tests into markets worth hundreds of million pounds and Sensitizer, their protein profiling toolkit, is tipped to...
Register now for FREE Proteome Sciences share price discussions